# Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

> **NCT04144348** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Human Metapneumovirus and Human Parainfluenza Infection

## Interventions

- **BIOLOGICAL:** mRNA-1653
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04144348
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-04
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144348, "Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04144348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*